Key Points
- Insider purchase: Victoria Hull bought 3,214 shares of Hikma on November 7 at an average price of GBX 1,547, a transaction worth about £49,720.58.
- Price and valuation snapshot: The stock opened at GBX 1,562.02, near its 52‑week low (GBX 1,522) and below the 50‑day (GBX 1,726.58) and 200‑day (GBX 1,891.43) moving averages; market cap ~£3.46bn and P/E ~9.35.
- Analyst outlook: Consensus rating is Buy with an average price target of GBX 2,416, although several brokers have recently trimmed individual targets.
Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Victoria Hull bought 3,214 shares of the stock in a transaction on Friday, November 7th. The stock was acquired at an average price of GBX 1,547 per share, with a total value of £49,720.58.
Hikma Pharmaceuticals Price Performance
Hikma Pharmaceuticals stock opened at GBX 1,562.02 on Tuesday. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a market capitalization of £3.46 billion, a price-to-earnings ratio of 9.35, a PEG ratio of 2.38 and a beta of 0.41. The stock's 50 day moving average price is GBX 1,726.58 and its two-hundred day moving average price is GBX 1,891.43. Hikma Pharmaceuticals PLC has a 52-week low of GBX 1,522 and a 52-week high of GBX 2,360.
Wall Street Analyst Weigh In
Several brokerages have issued reports on HIK. Deutsche Bank Aktiengesellschaft cut their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a report on Friday. Peel Hunt reaffirmed a "buy" rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research report on Friday. Berenberg Bank cut their price target on Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a "buy" rating for the company in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an "overweight" rating for the company in a research note on Friday. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of GBX 2,416.
Read Our Latest Analysis on Hikma Pharmaceuticals
About Hikma Pharmaceuticals
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
